Angels for Change is proud to announce a major Project PROTECT milestone: our partner Fagron Sterile Services is now fully production-ready with new U.S. capacity for Sterile Water for Injection—a critical component used in countless injectable medicines.
This marks the second successful Project PROTECT collaboration with Fagron, following earlier investments that helped protect patients during the IV fluid shortage in 2024. By investing in domestic manufacturing infrastructure, we’re strengthening the resilience of the U.S. drug supply and protecting patients before shortages occur.
We don’t just talk about ending drug shortages—we’re creating solutions that build onshore readiness, strengthen supply chains, and protect patient access to lifesaving medicines.
Laura Bray and Angels for Change highlighted in the newly released white paper from the API Innovation Center, “Fragility to Resilience: Aligning Investment and Purchasing to Secure America’s Drug Supply Chain.”
Bray emphasized a clear call to action for leaders across the healthcare ecosystem to work together to solve the drug shortage crisis:
“This is not the patient’s job to solve at all… This is a supply chain failure.”
Drug shortages are making national headlines again as families search for critical medicines like leucovorin. In a recent CNN article, Angels for Change founder Laura Bray highlights how the crisis was predictable—and preventable. Through Project GOLD, Angels for Change works across the supply chain to locate scarce medications and help patients access the treatments they depend on, because no family should have to face a shortage alone.
At Angels for Change, we are proud to participate in the important work of the End Drug Shortages Alliance — serving as both an EDSA member organization and advising partner in the Drug Resiliency & Transparency Pilot.
The initial phase of the pilot demonstrated a powerful truth: when leaders come together early through trusted, neutral governance, transparency delivers real planning value.
Angels for Change today announced that the Mark Cuban Cost Plus Drug Company has completed the Preparation and Protective phases of Project PROTECT for Carboplatin Injection and Methotrexate Injection—two essential oncology medicines currently in nationwide shortage. This milestone strengthens onshore readiness and improves supply availability for patients across the United States.
Laura Bray discusses the personal inspiration behind her nonprofit, Angels for Change in a December 2025 interview with Voyage Tampa. Motivated by her daughter's struggle with chemotherapy drug shortages, Bray transitioned from a business professor to lead an organization dedicated to solving pharmaceutical supply chain issues.
Congratulations to Project PROTECT, recently honored with the 2025 EDSA Catalyst Award for Outstanding Industry Collaboration from the End Drug Shortages Alliance. This award honors a multi-stakeholder partnership that has measurably improved drug access and strengthened supply resilience through cooperation, transparency, and innovation.
This award is especially meaningful because it reflects what Project PROTECT was built on from the very beginning: collaboration, ingenuity, and a shared commitment to protecting patients from essential medicine shortages. Together, Angels for Change, STAQ Pharma, and the Children’s Hospital Association designed and launched a model that brings hospitals, advocacy groups, manufacturers, and supply chain experts around one table to strengthen the stability of the drug supply chain.
A new WJLA Team investigation exposes how foreign-made chemotherapy drugs are failing quality tests or disappearing from hospitals — leaving patients without safe treatment options. The story features Angels for Change and Founder Laura Bray, whose experience navigating drug shortages during her daughter Abby’s cancer treatment inspired our mission to protect patients and end drug shortages nationwide.
The End Drug Shortages Alliance (EDSA), co-founded by Angels for Change and Vizient, has grown to more than 100 members across the healthcare supply chain. The article highlights how this expanding organization is advancing transparency, data-sharing and coordinated action to strengthen access to essential medicines. Recent progress includes a pilot with children’s hospitals and distributors focused on improving visibility for critical pediatric oncology drugs. The alliance’s continued growth reflects a shared commitment to building a more resilient, patient-centered supply chain.
Angels for Change celebrates the Senate’s passage of the National Defense Authorization Act (NDAA), which includes key provisions from the MAPS Act to strengthen transparency and coordination across the drug supply chain. This bipartisan step, led by Senators Peters, Lankford, Ernst, Cotton, Kaine, King, and Scott, advances meaningful progress toward a more reliable supply of essential medicines.
As the bill moves to the House, Angels for Change urges continued momentum to protect patients and prevent future drug shortages.
Angels for Change’s Project PROTECT has taken a significant step to strengthen preparedness for a lifesaving medicine, magnesium sulfate. In partnership with STAQ Pharma, magnesium sulfate is now ready for on-demand production, reinforcing resilience for a medicine essential to protecting mothers and newborns during emergencies and supply strain. This proactive readiness ensures patients receive vital treatment without delay.
Angels for Change was recently featured in an Understood.org article examining how the DEA’s adjustments to stimulant production limits may affect the ongoing ADHD medication shortage.
The article highlights the complex factors contributing to medication access challenges, including quota restrictions, manufacturing capacity, and rising demand.
When a child is told the medicine they need to live isn’t available — we must act for change. The Children’s Hospital Association’s new article, “Ensuring Access to Critical Medicines for Children,” shines a light on the shared effort to protect pediatric patients from drug shortages and features Angels for Change’s work to strengthen medicine access nationwide.
A4C Founder Laura Bray Authors Chapter in The Cancer Journal
We’re proud to share that A4C’s Founder and Chief Change Maker, Laura Bray, authored a chapter in The Cancer Journal. The piece takes a patient-centered approach to addressing drug shortages through a six-step pathway to a more resilient medicine supply chain.
Her chapter, “What an Oncology Drug Shortage Looks and Feels Like to Patients and What Can Be Done About It,” combines personal experience with actionable solutions to strengthen access to essential medicines.
“Ensuring patients receive care every single day, every single time, will take change. Patients deserve a resilient supply chain.” -Laura Bray, Angels for Change
We thank The Cancer Journal for dedicating an entire issue to this critical topic and elevating the voices of experts and advocates leading this work.
Hear from other Drug Shortage Experts in the full issue of The Cancer Journal below.
Read the PDF of Laura Bray’s chapter below.
SHARE YOUR “WHY”
Every conversation, partnership, and shared story brings us closer to a future without drug shortages. At Angels for Change, we’re proud to march forth for patients everywhere.
